Comparative Pharmacology
Head-to-head clinical analysis: PRILOCAINE HYDROCHLORIDE versus XYLOCAINE VISCOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRILOCAINE HYDROCHLORIDE versus XYLOCAINE VISCOUS.
PRILOCAINE HYDROCHLORIDE vs XYLOCAINE VISCOUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prilocaine hydrochloride is an amino amide local anesthetic that reversibly blocks sodium channels in nerve cell membranes, inhibiting nerve impulse propagation.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, inhibiting nerve impulse propagation and reducing pain sensation.
Adults: 4 mg/kg (max 200 mg) via infiltration or nerve block; may repeat after 2 hours with 50% of initial dose.
Adults: 5-15 mL orally (or swish and spit) 4-6 times daily, not to exceed 4 doses in 12 hours or 30 mL in 12 hours.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (adults, normal hepatic function). Prolonged in neonates (up to 8-12 hours) due to immature hepatic metabolism and reduced clearance; may cause methemoglobinemia. Hepatic impairment increases half-life.
Terminal elimination half-life: 1.5-2 hours in adults; prolonged in hepatic impairment or heart failure (up to 6-8 hours). In neonates, half-life may be 3-6 hours due to immature metabolism.
Renal: ~95% as metabolites (primarily o-toluidine and 4-hydroxy-2-methylaniline) and <5% unchanged. Biliary/fecal: minimal (<2%).
Renal excretion of metabolites: ~90%. Unchanged drug: <10%. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic